Everolimus is used as the main active ingredient in medicines. It is an inhibitor of cell proliferation and immunosuppressive agent. It is also used to prevent cellular rejection after organ transplantation with combination of certain medication. It is used in combination with other anticancer agents in the treatment of advanced renal cell and other cancers.
Class of Drugs – Immunosuppressants
Molecular Formula – C53H83NO14
Molecular Weight - 958.2 g/mol
Working: This active component is used to prevent rejection of a kidney transplant. It belongs to a class of drugs known as immunosuppressants. This medication weakens the body's defense system to help the body to accept the new organ as if it were its own.
Uses: The effective medicine is used for the treatment of postmenopausal women with advanced hormone receptor-positive, HER2negative breast cancer in combination with exemestane and in adult with progressive neuroendocrine tumors of pancreatic origin (PNET) with unresectable, locally advanced or metastatic disease.
Everolimus can be used to treat progressive, well-differentiated, non-functional NET of gastrointestinal (GI) or lung origin with unresectable and advanced RCC after failure of treatment with sunitinib or sorafenib.
It also approved for the treatment of SEGA that requires therapeutic intervention but cannot be curatively resected in adult and pediatric people aged 1 year and older with TSC i.e. Tuberous Sclerosis Complex
Popular Brands and Dosages:
- Afinitor: 5 mg and 10 mg
- Zortress: 5 mg and 10 mg
- Afinitor Disperz: 5 mg and 10 mg
Everolimus is not indicated for the treatment of people with functional carcinoid tumors.